Mangiacapra, Fabio <br/><br/>
Point-of-care assessment of platelet reactivity after clopidogrel to predict myonecrosis in patients undergoing percutaneous coronary intervention.  [electronic resource] 

 -  JACC. Cardiovascular interventions  Mar 2010 
 - 318-23 p.  digital 
<br/><br/> Publication Type: Evaluation Study; Journal Article 
<br/><br/><label>ISSN: </label>1876-7605 
<br/><br/><label>Standard No.: </label>10.1016/j.jcin.2009.12.012  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Angioplasty, Balloon, Coronary--adverse effects<br/>Biomarkers--blood<br/>Blood Platelets--drug effects<br/>Clopidogrel<br/>Coronary Artery Disease--blood<br/>Creatine Kinase, MB Form--blood<br/>Female<br/>Humans<br/>Logistic Models<br/>Male<br/>Middle Aged<br/>Myocardial Infarction--blood<br/>Myocardium--pathology<br/>Necrosis<br/>Odds Ratio<br/>Platelet Aggregation Inhibitors--therapeutic use<br/>Platelet Function Tests<br/>Point-of-Care Systems<br/>Predictive Value of Tests<br/>Purinergic P2 Receptor Antagonists<br/>Receptors, Purinergic P2--blood<br/>Receptors, Purinergic P2Y12<br/>Risk Assessment<br/>Risk Factors<br/>Ticlopidine--analogs & derivatives<br/>Time Factors<br/>Treatment Outcome<br/>Troponin I--blood